These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23840510)

  • 1. Tamoxifen and ovarian function.
    Berliere M; Duhoux FP; Dalenc F; Baurain JF; Dellevigne L; Galant C; Van Maanen A; Piette P; Machiels JP
    PLoS One; 2013; 8(6):e66616. PubMed ID: 23840510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
    Yamazaki R; Inokuchi M; Ishikawa S; Ayabe T; Jinno H; Iizuka T; Ono M; Myojo S; Uchida S; Matsuzaki T; Tangoku A; Kita M; Sugie T; Fujiwara H
    BMC Cancer; 2020 Jan; 20(1):67. PubMed ID: 31996163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tolerance of Tamoxifen as an adjuvant therapy and long-term follow up of 55 premenopausal breast cancer women, cared for at the Institut de cancérologie de Lorraine, treated with Tamoxifen].
    Sebaoun P; Frederic M; Weryha G; Hamdaoui SE; Salleron J; Lesur A
    Bull Cancer; 2019 Dec; 106(12S1):S75-S100. PubMed ID: 32008741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
    Guerrero A; Gavilá J; Folkerd E; Ortiz B; Martínez F; García A; Climent MA; Guillem V; Ruíz A
    Ann Oncol; 2013 Mar; 24(3):674-9. PubMed ID: 23108951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH
    Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
    Yasumura T; Oka T; Honjo H; Okada H
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
    [No Abstract]   [Full Text] [Related]  

  • 13. Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.
    Xue C; Peng R; Cao Y; Wang S; Shi Y; An X; Xu F; Yuan Z
    PLoS One; 2016; 11(2):e0148849. PubMed ID: 26866810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
    Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
    J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
    Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
    Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
    Swain SM; Land SR; Ritter MW; Costantino JP; Cecchini RS; Mamounas EP; Wolmark N; Ganz PA
    Breast Cancer Res Treat; 2009 Jan; 113(2):315-20. PubMed ID: 18302020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.
    Tang S; Zhang Q; Tang X; Chen D; Zhang F; Liu J; Wei W; Liu D
    J Int Med Res; 2019 Feb; 47(2):641-652. PubMed ID: 30354917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
    Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
    J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.